Progress in the management of childhood asthma by Vichyanond, Pakit et al.
Current Review Asia Pacific
allergy
pISSN 2233-8276 · eISSN 2233-8268
http://dx.doi.org/10.5415/apallergy.2012.2.1.15
Asia Pac Allergy 2012;2:15-25
Progress in the management of childhood 
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Asthma has become the most common chronic disease in childhood. Significant advances in epidemiological research as well as in 
therapy of pediatric asthma have been made over the past 2 decades. In this review, we look at certain aspects therapy of childhood 
asthma, both in the past and present. Literature review on allergen avoidance (including mites, cockroach and cat), intensive therapy 
with β2-agonists in acute asthma (administering via continuous nebulization and intravenous routes), a revisit of theophylline use and 
its action, the use of inhaled corticosteroids in various phases of childhood asthma and sublingual immunotherapy in asthma are 
examined. Recent facts and dilemmas of these treatments are identified along with expression of our opinions, particularly on points 
of childhood asthma in the Asia-Pacific, are made in this review. 
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IntroductIon  
International epidemiological studies on allergic diseases in 
children (the ISAAC-I and ISAAC-III) indicated that prevalence of 
childhood asthma is increasing worldwide, including among 
countries in Asia [1, 2]. Apparently, such increase could not be 
explained by changes that occurred in genetic alone, but rather 
by a combination of changing in environmental milieu, and 
changing in lifestyles which exerted effects on gene expression, 
resulting in increasing various phenotypes of asthma in children. 
Despite progress in molecular research such as the completion 
of the human genome project, the availability of technologies 
to perform genome-wide association studies and knowledge 
on epigenetics, clinical application of such knowledge on the 
treatment of asthma is still far from possible. Current treatment of 
childhood asthma is still mainly depending on pharmacological 
approach and on modification of immune response to allergens 
causing IgE sensitization. 
The purpose of this article is to review some aspects of 
available treatment of childhood asthma with main emphasis 
on commonly used drug therapy for asthma (β2-agonists, 
theophylline and corticosteroids) along with avoidance of 
common allergens causing sensitization among asthmatic 
children. Last but not least, sublingual immunotherapy, a 
growing area of immunomodulation, particularly suitable for 
young children, is also reviewed. 
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Allergen avoidance 
The latest US - National Asthma Education and Prevention 
Program asthma guidelines (NAEPP 2007) still recommends 
allergen avoidance as a basic part of management asthma [3]. In 
the PRACTALL 2008 document (a practical guidelines for diagnosis 
and treatment of asthma in childhood – published jointly by the 
American Academy of Allergy, Asthma and Immunology and 
the European Academy of Allergy and Immunology), allergen 
avoidance is recommended when there is sensitization and a 
clear association between allergen exposure and symptoms [4]. 
The Global Initiatives of Asthma (GINA) 2009, recommended 
allergen avoidance as a part of regimen for prevention asthma 
symptoms and exacerbations [5]. Morgan et al. [6] conducted 
a one-year controlled trial of environmental interventions for 
children with asthma. They found that the intervention group had 
fewer days with symptoms than the control group. The reduction 
of Dermatophagoides pteronyssinus (Der p 1), Dermatophagoides 
farinae (Der f 1) and cockroach allergens was significantly lower 
in the intervention group than in the control group. Despite 
such recommendation, a recent meta-analysis for house-
dust mites (HDM) control in asthma, showed no statistically 
significant difference either in the numbers of patients who 
improved, asthma symptom scores and medication usage in 
the intervention group [7]. Such analysis concluded that HDM 
avoidance is ineffective in the treatment of asthma. However, trials 
included in the analysis were heterogeneous in methods of mite 
elimination, results of allergen reductions, patients’ characteristics 
and outcome of management. Moreover, some large trials with 
positive results were excluded from the analysis. For such reasons, 
it is difficult to apply the results of such meta-analysis in a day-to-
day management of allergic diseases [8] and most guidelines still 
endorse environmental control as a part of their recommendations. 
HDM 
In most humid areas around the world, house dust mites are the 
major sources of allergens found in house dust. The most common 
species of house dust mites are Der p and Der f. 
To date, approximately 22 to 23 different HDM allergens have 
been identified, with Der p 1 and Der f 1 being the major allergens 
causing sensitization among mite-sensitive individuals. Mite fecal 
particles are the abundant sources of mite allergens [9]. Size of 
these particles can vary from large particles (over 100 µm) to those 
in respirable sizes (<10 µm). Mite allergens collect in bedding 
materials. The highest mite concentrations can be found in dusts 
from mattresses. It has been shown that dust mite exposure in 
early life is a major risk factor for future development of asthma 
[10]. Moreover, exposure to large amount of mite allergen leads to 
asthma exacerbations [11, 12]. 
Current recommendations for treatment of asthma (GINA) and 
allergic rhinitis (ARIA) includes measures for reduction of exposure 
to house dust mite allergens. These measures are:
1.     Use of mite impermeable encasement for mattresses, pillows 
and other bedding material. Woven fabrics with pore size less 
than 10 µm are preferred [13]. Studies on effect of impermeable 
covers for mattresses on Der p 1 and Der f 1 concentrations 
showed mite-impermeable covers are effective in reducing 
levels of Der p 1 and Der f 1 after 12 months of study [14, 15]. 
The study by Halken et al. [15] found encasing of mattresses 
and pillows resulted in a significant long-term reduction in 
mite allergen concentrations in mattresses and in the need for 
inhaled steroids in asthmatic children with mite allergy.
2.    Washing bed clothing in hot water (over 55ºC) can kill mites 
and reduce mite allergen concentrations by 90% [16]. Washing 
at room temperature has also been shown remove allergen 
from bed clothing. Freezing condition will also kill mites. Thus, 
stuffed animal may be placed in plastic bag in freezer before 
washing to remove left over allergen [17].
3.    Carpets and upholstered furniture are major source of mite 
collections. Ideally, carpets should be replaced with polished 
wood or vinyl floor covering. Exposure of thin carpets to direct 
strong sunlight for at least 3 h has been found to eliminate 
mites [18]. However, this method is perhaps not applicable to 
thicker and wall-to-wall carpets. 
Cockroach
Exposure to cockroaches has been found to be an important 
factor in the development of childhood asthma in inner-city 
environment of the United States [19]. The two major cockroach 
species are the American cockroach (Periplanata Americana) and 
the German cockroach (Blattella germanica). Blatella germanica is 
the major cockroach species found in the United States whereas 
Periplanata Americana are found in Thailand and throughout Asia 
[20]. 
Cockroach avoidance
Both physical and chemical measures have been used to control 
cockroach populations in the household. Patients and families 
should be instructed to properly discard left-over food and liquids apallergy.org
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which can be source of nutrients for cockroaches. Chemicals used 
for cockroach extermination are abamectin, hydromethylnon 
and pyrethrin [21]. The most effective form appears to be gel, 
which is commonly placed in the cockroach bait station or even 
as a quick hardened gel in several sites in the household. Such 
treatment, together with family education, will be effective in 
reducing cockroach populations for 2-3 months [22]. Treatment 
by professional entomologists was found to be more effective 
in reducing cockroach allergen when compared to treatment by 
chemical companies [23]. Reduction in cockroach allergen can be 
achieved through combined intervention of occupant education, 
insecticide application and professional cleaning [6]. 
Pet allergen (cats and dogs) 
The role of pet elimination in primary allergy prevention is still 
controversial. However, exposure to pets by sensitized individuals 
can aggravate allergic symptoms including asthma [24]. Because 
cat allergen exposure has also been shown to occur outside the 
home, particularly in schools, pet avoidance in the home alone 
may not be sufficient in reducing exposure to cat allergens. Cat 
allergens are found in 90% of all home and most public indoor 
areas even in homes of those without pets [25].
Pet avoidance
1.    Removal of the animal from home. The best way to reduce 
exposure to cat or dog allergens is to remove the animals from 
home. It may take months (20-24weeks) after cat removal to 
achieve reduction of cat allergens to the normal level [26]. 
Cleansing of washable surfaces should be undertaken once 
pets are removed. For those who could not remove the animals, 
pets should be kept outdoor. Cat and dog washing can reduce 
allergen in the furs, but the effect is of short duration. Also, 
dog washing had to be done at least twice a week which is not 
physically possible to most families [27]. 
2.    Control of airborne pet allergen levels in the home by air 
cleaners. Although high-efficiency particulate air filter was 
found to effectively reduce airborne cat allergen levels, there 
was insufficient evidence for the reduction of associated disease 
activities [28]. In a recent Cochrane analysis for determining 
the efficiency of air filtration unit in allergy to pets, only 2 
smalls studies were found and no differences in clinical efficacy 
between intervention and control groups was demonstrated 
[29]. 
Short-acting β2-agonists in acute asthma
Continuous β2-agonists nebulizer for acute asthma 
There is a general agreement that short-acting β2-agonists such 
as albuterol (salbutamol) and terbutaline are the first-line agents 
for the treatment of acute asthma due to its rapid bronchodilating 
action. Since the late 1980s, uncontrolled studies in asthmatic 
children have demonstrated that β2-agonists (terbutaline) could 
be safely and effectively administered by continuous nebulization. 
Moler et al. [30] studied 19 children and found that continuous 
nebulization of terbutaline (4 mg/h) was effective in improving 
clinical scores and in decreasing arterial carbon dioxide tension 
(PaCO2). No significant toxicity was recorded during treatment 
lasting up to 37 h. Portnoy et al. [31] found that 12 patients 
treated with continuous nebulized terbutaline (1-12 mg/h for 
1-24 h) had an improvement in gas exchange and respiratory 
rate within an average of 8 h. No significant toxicity was noted 
and all 12 patients were discharged from the intensive care 
unit within 24 h. In a study by the same authors, 26 children 
with severe exacerbations of asthma unresponsive to systemic 
theophylline, methylprednisolone and intermittent β2-agonist 
inhalation, continuous nebulized terbutaline administered at 
doses of 1-12 mg/h, for a mean duration of 7-8 h (range 1-24 h) 
caused clinical scores to improve rapidly and all patients showed 
marked improvement in pH and PaCO2 during the first 2 h [32]. 
A prospective randomized study by Papo et al. [33] treated 
17 children with impending respiratory failure due to status 
asthmaticus with either continuous or intermittently nebulized 
salbutamol (0.3 mg/kg/h or 0.3 mg/kg over 20 min every h). As 
judged by the clinical score and blood gas values, the children 
in the continuous nebulization group improved faster and spent 
less time in hospital than those receiving intermittent treatment. 
No side effects were seen. It was quite apparent that continuous 
nebulization of either terbutaline or salbutamol was effective 
among hospitalized children with severe asthma. Surprisingly, 
when continuous nebulization was compared with intermittent 
nebulization among 2-18 years old patients presented with severe 
asthma in the emergency department (ED) setting, no difference 
in hospitalization rate was observed [34]. However, in this study, 
continuous therapy provided a significant time savings in the 
delivery of asthma therapy to patients in a busy ED. 
For adult asthma, a systematic review of randomized controlled 
trials (6 studies) showed the equivalence of continuous and 
intermittent albuterol nebulization in term of pulmonary apallergy.org
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function and hospital admission [35]. However, in an ED setting, 
a subgroup analysis among more severe patients with an initial 
peak expiratory flow rates (PEFRs) of 200 or less, continuous 
nebulization decreased admission rate and improved PEFRs 
when compared with intermittent therapy [36]. Camargo et al. 
[37] published a Cochrane systematic review of continuous vs. 
intermittent β2-agonists for acute asthma (8 trials and 1 in children) 
and concluded that differences were found between the two 
methods, with continuous nebulization producing a modest 
reduction in admissions compared to intermittent beta-agonist 
therapy. This finding was more pronounced in severe acute 
asthma. Continuous nebulizing therapy may be more effective 
than intermittent nebulization for delivering beta-agonist drugs to 
relieve airway spasm in selected asthma populations. Moreover, 
continuous treatment appears to be safe and well tolerated.
Intravenous (IV) β2-agonists for acute asthma
The general approach for treating patients with severe acute 
asthma is to use β2-agonist bronchodilators and corticosteroids. For 
rapid bronchodilation among these severe patients, penetration 
of inhaled drug to the affected small conducting airways may 
be impeded. In these circumstances, IV rather than inhaled 
administration of bronchodilators may provide an earlier clinical 
response. Stephanopoulos et al. [38] found that IV terbutaline 
was well tolerated in asthmatic children for up to 305 continuous 
h, at varying doses up to a maximum of 10 μg/kg/min without 
significant elevation of CPK-MB. Arrhythmia was rare and only 
two occasions of ST-depression was observed. In a randomized, 
double-blind, placebo-controlled trial of IV salbutamol (15 µg/kg 
as a single bolus over 10 min) vs. nebulized ipratropium bromide 
(250 µg), or IV salbutamol plus ipratropium bromide in an early 
management of severe acute asthma in children presenting to 
an emergency department, children who received IV salbutamol 
for severe acute asthma showed a more rapid recovery time, 
which resulted in earlier discharge from the hospital than those 
administered inhaled ipratropium bromide [39]. There was no 
additional benefit obtained by combining ipratropium bromide 
and IV salbutamol administration. For a safety concern, a 
retrospective study of admission records of 77 children admitted 
with acute severe asthma who needed IV terbutaline showed that 
there was a significant increase in heart rate and a significant fall 
in diastolic blood pressure among this cohort [40]. Four patients 
required inotropic support. None of the patients had cardiac 
arrhythmias. Potassium supplements were required in 10 patients 
due to hypokalaemia. All patients improved and none required 
initiation of artificial ventilation after commencing terbutaline. 
There was no mortality in this cohort. 
For treatment in the ED, guidelines in North America and 
Europe still recommend inhaled β2-agonist therapy for all cases of 
asthma presenting to emergency departments [3, 41, 42]. IV and 
subcutaneous β2-agonists are described as second line therapy 
for use in patients unresponsive to inhaled bronchodilator and 
systemic corticosteroid therapy, or if the inhaled route is not 
practical for such patients. Travers and Jones recently published 
a systematic review of IV β2-agonist for acute severe asthma in 
the ED and concluded that there is no evidence to support the 
advantage of the use of IV β2-agonists over inhaled β2-agonists 
limiting its use (IV route) in the ED situation [43].
Theophylline in the management of asthma in children, a re-
visit
Theophylline, a methylxanthine with a structure similar to 
xanthines found in coffee and tea, was isolated by the end of the 
19th century. However, its use in asthma was not begun until after 
Hirsch described its bronchodilating effect [44]. Aminophylline, a 
soluble ethylenediamine salt of theophylline, was later developed 
for IV administration and was shown to be effective in acute 
severe asthma, particularly in patients who had not responded 
well to adrenaline [45]. Subsequently, its oral preparation, in fixed 
dose combination with ephedrine and phenobarbital, was later 
described [46] and was soon followed by the introduction of rapid 
release formulation [47]. Due to its low cost, oral theophylline 
became a very popular treatment for asthma, between the 1960’s 
to 1980’s, worldwide. However, because its short duration, slow-
release theophylline formulations, that could be given once or 
twice daily, was later developed and became a standard of chronic 
therapy in the late 1970’s for asthma due to their convenience and 
greater tolerability. Early dose–response studies demonstrated an 
increasing bronchodilator response above plasma concentrations 
of 10 µg/mL (55 μM) [48]. The upper recommended plasma 
concentration was 20 µg/mL due to unacceptable side effects 
above this level (headache, nausea, cardiac arrhythmia and 
convulsion). The therapeutic range for plasma concentrations was 
therefore established to be between 10 to 20 µg/mL. Doses should 
be adjusted individually due to interpersonal pharmacokinetic 
variations.
Since theophylline has a narrow therapeutic window, its 
use in acute asthma in children in the late 1980’s was mainly apallergy.org
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for those who did not respond adequately to inhaled β2-
agonists and particularly for those who required hospitalization. 
Some investigations conducted to determine the effect of IV 
theophylline in addition to inhaled β2-agonists showed varying 
clinical results [49]. However, the results of a study of 163 children 
with acute severe asthma by Yung and South [50] showed that 
the aminophylline group had better spirometry results at 6 h with 
better oxygen saturation at 30 h compared to placebo. Moreover, 5 
of the placebo group required endotracheal intubation compared 
to none in the aminophylline group. Of note in this study was all 
patients were given IV and oral corticosteroids. In 2005, recent 
Cochrane analysis by Mitra [51], analyzing 7 randomized controlled 
trial comparing aminophylline and placebo in 380 children with 
acute asthma who required hospitalization. The results indicated 
that those receiving aminophylline had no difference in length of 
hospital stay, symptoms, frequency of nebulizations, mechanical 
ventilation rates comparing to those receiving placebo. Together 
with the introduction of newer methods, devices for effective use 
of continuous nebulization of β-agonist in asthma [32], the use of 
IV aminophylline in acute asthma in children came to an almost 
complete halt with its use only limited chronic asthma. 
Mechanism of action of theophylline in asthma 
Although theophylline has been in clinical use for many years, 
its mechanism of action remains uncertain. Although it is generally 
considered to be a bronchodilator, evidence indicates that it 
may also have important immunologic and anti-inflammatory 
properties.
Bronchodilating action of theophylline
The molecular mechanism of bronchodilatation has been 
largely been ascribed to its ability to inhibition action of 
phosphodiesterase enzyme (PDE) which degrades cyclic AMP 
(cAMP) and cyclic GMP (cGMP). This results in an increase in 
cAMP and thereby leads to bronchodilation. Theophylline is a 
nonselective PDE inhibitor and the degree of PDE inhibition is 
small at concentrations of theophylline which are therapeutically 
relevant. In fact, total PDE activity in human lung extracts 
is inhibited by only 5-20% at therapeutic concentrations of 
theophylline [52]. Therefore, bronchodilation through PDE 
inhibition may not be the only mechanism and other mechanisms 
such as interference with K-maxi channel regulation was described 
[53]. Theophylline is also a potent inhibitor of adenosine receptors 
at therapeutic concentrations, with antagonistic action towards 
A1- and A2-receptors although it is less effective against A3-
receptors [54]. Adenosine antagonism is likely to account for some 
of the serious side effects of theophylline, such as seizures and 
cardiac arrhythmias. 
Theophylline has been shown to affect respiratory muscle. It 
increases diaphragmatic muscle contractility and strength [55]. 
This effect may be a mechanism for the small but significant 
decrease in the work of breathing demonstrated for theophylline 
[56].
   
Anti-inflammatory action
In allergen challenge studies in patients with asthma, IV 
theophylline inhibits late response to allergen, but had relatively 
little effect on the early response [57]. This has been interpreted as 
an effect on chronic inflammatory response, which is supported 
by a reduction of infiltration of eosinophils and CD4
+ lymphocytes 
into the airways after allergen challenge subsequent to low doses 
of theophylline [58]. In patients with nocturnal asthma, a low-
dose theophylline inhibits the influx of neutrophils and, to lesser 
extent eosinophils in the early morning [59]. In vitro, theophylline 
was found to increase interleukin-10 release from peripheral 
blood mononuclear cells stimulated with mitogens [60]. 
These anti-inflammatory effects of theophylline in asthma and 
COPD are seen at concentrations that are usually less than 10 µg/
mL, which is below the dose with associated with clinically useful 
bronchodilatation. Theophylline in low therapeutic concentrations 
has been shown to activate the nuclear enzyme histone 
deacetylase which switches off the transcription of activated 
inflammation genes. Such action is synergistic with corticosteroids 
[61] and thus, low concentration of theophylline could restore 
corticosteroid repression of pro-inflammatory mediator release and 
histone acetylation in oxidant exposed cells [62]. This interaction 
may open up possibilities for novel anti-inflammatory therapies in 
the future.
Theophylline use in chronic asthma
GINA asthma guidelines recommend theophylline as add 
on therapy in patients who do not achieve control on inhaled 
corticosteroids alone [5]. As add-on therapy, theophylline is less 
effective than long-acting inhaled β2-agonists [63, 64]. A Cochrane 
Database of Systematic Reviews in 2007 reviewed the comparative 
efficacy, safety and side-effects of long-acting β2-agonists and 
theophylline in the maintenance treatment [64]. All included 
studies were RCTs involving adults and children with clinical apallergy.org
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evidence of asthma. These studies compared oral sustained 
release and/or dose adjusted theophylline with an inhaled long-
acting β2-agonist in adults and adolescents with asthma. Thirteen 
studies with a total of 1,344 participants met the inclusion criteria 
of the review. Salmeterol was related with a greater improvement 
in lung function, and reduced the need for extra short-term 
inhalers in the day and the night. Salmeterol and formoterol were 
less likely to produce side-effects (such as headaches and nausea) 
when compared to theophylline [64].
Surprisingly, in a study by Evans et al. [65] low-dose inhaled 
budesonide with theophylline produced similar benefits on 
improvement lung function and reductions in β2-agonists use 
when compared to high-dose inhaled budesonide, in adult 
patients with moderate asthma and persistent symptoms. In 
a recent meta-analysis in pediatric asthma population [66], 
xanthine was found to be more effective than placebo as first-line 
maintenance therapy. It was less efficient than inhaled steroids but 
was similar to short-acting β2-agonists and sodium cromoglycate. 
The reviewers, however, did not find any evidence to support the 
synergy between xanthine and inhaled steroids. 
 
Inhaled corticosteroids (ICS) in pediatric asthma
Effectiveness of inhaled steroids in chronic asthma 
ICS became available for the treatment of asthma in the early 
1960’s. However, it use was not popular until the late 1970’s due 
to limited understanding of pathophysiology of asthma and 
‘steroid phobia’ among physicians, patients and parents alike. 
Together with availability of newer ICS’s with increased potency, 
reduced systemic absorption and extensive hepatic first-pass 
degradation (such as budesonide and fluticasone) along with 
increasing understanding that inflammation of the lungs as the 
pathophysiologic basis of asthma, the use of ICS in asthma became 
rapidly accepted among pediatric allergists as well pediatricians. 
Administration of ICS to moderately severe asthmatic children led 
to a rapid decrease symptoms within 2 weeks [67]. In addition, ICS 
prevents asthma exacerbation in moderate to severe asthmatics 
both in adults [68] and children [69]. ICS is currently recommended 
as a first-line controller for ‘persistent’ asthma in most guidelines 
(NAEPP, PRACTALL, GINA). Beclomethasone dipropionate (BDP), 
despite being the first ICS with long standing clinical safety, has 
become less popular among pediatricians due to report of side 
effects on growth in children [70]. Currently, budesonide and 
fluticasone propionate are the two major recommend ICS for 
pediatric use, although data for fluticasone [71] are relatively 
limited as compared to budesonide [72].
Use of inhaled steroids early in asthma and to prevent 
progressive loss of lung function 
Since asthma is essentially an inflammatory disease of the 
lungs, progressive loss of the lungs has long been proposed. 
Indeed a long-term decline of lung function in chronic asthma in 
adults were reported by Lange et al. [73]. Agertoft and Pedersen 
reported a landmark findings of long-term use of budesonide 
(3 years) in a large number of asthmatic children, in which they 
reported that budesonide use was not only associated with lower 
rate of hospitalizations but also with a larger improvement of FEV1 
[74]. Remarkably, it was demonstrated that children who started 
ICS later in their course of disease (>5 years) attained lower lung 
growth than those used early (<2 years). After such observation, 
two large investigations were carried to verify such contention, i.e, 
the Childhood Asthma Management Program (CAMP in the USA) 
and the Inhaled Steroids As Regular Treatment in Early Asthma. A 
large numbers of publications have been generated from these 
two multicenter and premium studies. It was apparent that the use 
of ICS is constantly associated with lower degree of exacerbations 
of asthma but results on lung growth were not conclusive (not 
consistent in preventing decline in lung function as a whole but 
may/may not prevent the decline in severe patients) [75-78]. From 
the CAMP study, it was suggested that ICS were used too late in 
the course of disease (mean age of patients = 9 years old);instead 
of comma the same group of investigators (Childhood Asthma 
Research and Education Network USA – CARE network) further 
conducted a study using fluticasone propionate in wheezing 
toddlers with positive asthma predictive index [79]. The result of 
this ‘PEAK’ study again failed to show effect of ICS as a preventer 
(not preventing further development of asthma exacerbations 
after discontinuation of 2 years of use of ICS [80]). Thus, ICS is truly 
a ‘controller’ rather than a ‘preventer’ for asthma, as was previously 
conceived. 
Use of inhaled steroids in acute asthma 
Traditionally, ICS is used as a controller for chronic asthma. 
However, using high dose ICS in lieu of systemic steroids such as 
prednisolone was as attractive approach in order to avoid steroids 
side effect. Volovitz et al. [81] compared short-term use of high 
dose (1,600 µg) of budenoside with 2 mg/kg of prednisolone in 
a small group of children in the ED and found that there were apallergy.org
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similar improvement in pulmonary index score and peak flow rate 
in both group. Levy and his group [82] compared short courses 
of prednisolone with inhaled fluticasone in a large group of adult 
asthmatics (double-blind, double dummy, parallel trial) with mild 
exacerbation of asthma and demonstrated that both treatment 
group had similar treatment failure (prednisolone = 23% and 
fluticasone = 27%). Rodrigo and Rodrigo [83] compared very high-
dose of inhaled flunisolide given through volumatic spacer (6 mg 
per h for 3 h) vs. placebo in adult asthmatics with severe asthma 
(FEV1 < 50%) and found that patients in the flunisolide group 
improved significantly over placebo, from 90 to 180 min of therapy. 
It therefore appeared that ICS was effective in acute asthma in 
adult patients. In the year 2000, a pediatric study by Schuh et 
al. [84] comparing a single high-dose of inhaled fluticasone (2 
mg) via MDI with spacer with 2 mg of prednisolone in severe 
asthmatics (FEV1 < 60%) was published. At 4 h of treatment, 31% 
of patients in the fluticasone group were hospitalized compared to 
10% in the prednisolone group. The same group of investigators, 
later published a comparison (high-dose fluticasone vs. oral 
prednisolone) with longer therapy duration (5 days) in a less 
severe group of asthmatic children (FEV1 50-79%) [85]. Again, oral 
prednisolone showed higher improvement of lung functions at 
4 h (FEV1) and with less relapse rate at 48 h (prednisolone 0% vs. 
fluticasone 12.5%). In the 2003 Cochrane analysis by Edmonds 
et al. [86] among 5 trials in adults and 5 in pediatric population, 
ICS use was found to reduce rate of hospitalization as compared 
to placebo. However, among the 7 trials comparing ICS with oral 
steroids, there were significant heterogeneity among trials to 
preclude meaningful pooling of the results [86]. 
Use of inhaled steroids intermittently in mild persistent asthma
GINA and NAEPP recommend that patients with asthma should 
attain the ‘controlled’ condition prior to decrease controllers 
[3, 5]. The major question is when to discontinue controller, 
particularly ICS, in patients with less degree of severity. In the 
GINA recommendation, discontinuation of ICS is recommended 
when a patient does not have an exacerbation for 1 year. The 
recommendation for NAEPP is less stringent (2 episodes per year). 
Such recommendations pose a significant burden to patients, 
family and caretakers alike, particularly those with less frequent 
attacks. In the authors ‘experience, several patients opted to 
discontinue ICS on their own and used ICS on an intermittent 
basis. Recently, Boushey et al. [87] evaluated 225 adults with 
mild persistent asthma treated with daily ICS vs. daily zafirlukast 
vs. intermittent ICS or oral steroids. Frequency of exacerbations 
and peak flow rates were surprisingly similar among the three 
groups suggesting that in mild intermittent asthma, patients 
could be weaned to intermittent use of ICS. Recently, two major 
studies in pediatric populations were published to confirm the 
results in adults. In the Treating Asthma to Prevent Exacerbation 
study by Martinez et al. [88], 843 adolescent and children with 
mild intermittent asthma were studied. The group randomized 
to receive BDP with albuterol as rescue treatment did better than 
albuterol alone group with respect to exacerbations and treatment 
failure [88]. The daily ICS group provided the best results followed 
by the combined (daily ICS + rescue ICS with albuterol). The 
author suggested that pediatric patients with mild intermittent 
asthma may be considered weaned to rescue ICS + albuterol 
when considered appropriate. Most recently, the Maintenance 
and Intermittent Inhaled Corticosteroids in Wheezing Toddlers 
therapy published by Zeiger et al. [89] indicated that intermittent 
use of nebulized budesonide (1 mg twice daily) was as effective 
as daily budesonide (0.5 mg nightly) with respect to frequency of 
exacerbations and asthma severity. 
Allergen immunotherapy in asthma 
Specific allergen immunotherapy (SIT) has been one of the 
most debated aspects in the field of asthma treatment for several 
decades. Various reviews reported contradictory results of SIT 
in asthma, not only for adults, but also for children. Despite the 
presence of limitations and confounding factors, there were some 
evidences available to suggest that both subcutaneous (SCIT) and 
sublingual (SLIT) immunotherapy may be a viable treatment for 
asthma. We review recent advances of SLIT in pediatric asthma. 
SLIT and asthma
There are more than 60 randomized control trials of SLIT. Few 
trials have been specifically designed for asthma. A large number 
of studies were performed in children, particularly with house dust 
mites [90-92]. Most studies reported that SLIT can reduce asthma 
symptom scores and medication use [93, 94].  SLIT has been 
evaluated among Asian children who were sensitized to mites 
in at least 3 studies [92, 94, 95]. Most of these studies showed 
satisfactory results. In both trials from Taiwan, improvement in 
spirometry parameters was also observed [94, 95].
Calamita et al. [96] were the first to perform a meta-analysis 
on SLIT in asthma (including adults and children) asthma. They 
reported a significant difference between SLIT and placebo for apallergy.org
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categorical outcomes (better/unchanged/worsened), but not in 
the difference using the symptoms or medication scores of asthma. 
Nevertheless, there was high degree heterogeneity among studies 
(dose, duration, and outcome measures) thus limited some extent 
the positive conclusion. In 2008, a meta-analysis of effective of 
SLIT in pediatric asthma patients 3 to 18 years of age was reported 
by Penagos et al. [97]. The analysis included 441 patients from 
9 studies (5 mites 2 pollen, and 1 with mixed allergens). Overall 
results found a significant reduction in both symptoms (SMD 
−1.14; 95% CI −2.10 to −0.18, p = 0.02) and medication use (SMD 
−1.63; 95% CI −2.83 to −0.44, p = 0.007). However, again, there 
was a high degree of heterogeneity between studies. Problems 
of meta-analysis are high heterogeneity across studies, variation 
in studies, pool allergen use and dosages. In contrast, there 
were 3 studies randomized controlled trial reported no effect on 
asthma symptom scores [98-100]. Two studies showed almost 
no symptom of asthma at baseline and during trials (due to 
concomitant pharmacotherapy and environmental control to 
mites) and thus leaving for no room for improvement of the 
intervention examined.
Safety of SLIT
SLIT was found generally found to be safer than SCIT. No fatality 
has been reported with SLIT. Only 6 clinical cases of anaphylaxis to 
SLIT have been published. In a post marketing surveillance study 
of SLIT among pediatric patients (96,000 SLIT doses of extract 
administered), local side effects were mild, i.e., throat irritation and 
oral itching [101]. Only 3% of patients or 0.083 per 1,000 doses were 
associated with side effects. Seven systemic side effects, including 
abdominal pain, conjunctival itching, and rhinitis were noted. 
Most of these reactions were mild and required no treatment. No 
life-threatening events occurred. Neither fatal reaction nor need 
for hospitalization was observed [97]. Most of SLIT studies utilized 
continuous regimen with maintenance vaccine giving all year 
round. However, co-seasonal ultra-rush administration of SLIT to 
birch pollen has recently been reported to be efficacious and safe 
[102]. SLIT appeared to be a well tolerated and safe treatment for 
pediatric asthma.
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